TNFAIP3 gene in ankylosing spondylitis and psoriatic arthritis
Part of Bones, joints & muscles clinical trials.
This study looks at a specific gene (TNFAIP3) in people with ankylosing spondylitis or psoriatic arthritis to see if it relates to how active their disease is. It may help researchers understand these conditions better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of ankylosing spondylitis (using modified New York criteria) or psoriatic arthritis (using CASPAR criteria).
- You cannot have erythrodermic or pustular psoriasis.
- You cannot be pregnant or breastfeeding.
- You cannot have another autoimmune disease like lupus or a major systemic disease.
- You cannot be taking any immunosuppressive drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene (TNFAIP3) in people who have had immune-mediated thrombotic thrombocytopenic purpura (iTTP). It aims to understand how this gene might be linked to the condition. Participants will provide a blood or DNA sample for genetic testing.
This study looks at a protein called Tim-3 on certain white blood cells (neutrophils) in people with ankylosing spondylitis, to understand inflammation better. It may help find new ways to treat the condition.
This study looks at how often people with inflammatory bowel disease (IBD) who take TNF inhibitor drugs develop a type of arthritis in the spine (axial spondyloarthritis). It also checks how well the TNF inhibitors control the arthritis symptoms.
This study looks at how your immune system responds to starting infliximab or adalimumab for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Results may help doctors understand why some people don’t respond as well and how to improve treatment.
This research study measures a specific blood protein (IL-41) in people with two types of inflammatory arthritis: ankylosing spondylitis (which affects the spine) and psoriatic arthritis (which affects joints and skin). Understanding this marker may help doctors better diagnose and monitor these conditions.
This study looks at how a body signal called IL-23 may drive inflammation in spondyloarthritis (including joints) using samples from your care. It may help researchers identify which body cells and targets are involved, and how treatments could work better for active disease.
Hear when a new Ankylosing Spondylitis and Psoriatic Arthritis Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.